Vir CEO George Scangos (L) and chief corporate affairs officer Bolyn Hubby
In post-Covid life, Vir looks to stomp out influenza in up to $1B BARDA contract that boosts GSK-allied mAb
With its Covid-19 monoclonal antibody sidelined in the US since April and plans for full approval no longer in the cards, Vir Biotechnology is putting more eggs into the influenza basket with a hefty-sized contract from the federal government.
A capital infusion will bankroll a US-only Phase II testing Vir’s mAb as a pre-exposure prophylaxis to safeguard against seasonal and pandemic flu. The safety, efficacy and tolerability trial will kick off later this fall and read out initial data around next summer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
